MaaT Pharma Management

Management criteria checks 1/4

MaaT Pharma's CEO is Herve Affagard, appointed in Dec 2014, has a tenure of 9.92 years. total yearly compensation is €1.37M, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 1.68% of the company’s shares, worth €1.68M. The average tenure of the management team and the board of directors is 1.4 years and 4.5 years respectively.

Key information

Herve Affagard

Chief executive officer

€1.4m

Total compensation

CEO salary percentage	21.9%
CEO tenure	9.9yrs
CEO ownership	1.7%
Management average tenure	1.4yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Herve Affagard's remuneration changed compared to MaaT Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€24m
Mar 31 2024	n/a	n/a	-€22m
Dec 31 2023	€1m	€300k	-€20m
Sep 30 2023	n/a	n/a	-€17m
Jun 30 2023	n/a	n/a	-€15m
Mar 31 2023	n/a	n/a	-€14m
Dec 31 2022	€734k	€292k	-€14m
Sep 30 2022	n/a	n/a	-€13m
Jun 30 2022	n/a	n/a	-€12m
Mar 31 2022	n/a	n/a	-€11m
Dec 31 2021	€279k	€198k	-€9m
Sep 30 2021	n/a	n/a	-€8m
Jun 30 2021	n/a	n/a	-€7m
Mar 31 2021	n/a	n/a	-€6m
Dec 31 2020	€831k	€233k	-€5m

Compensation vs Market: Herve's total compensation ($USD1.49M) is above average for companies of similar size in the French market ($USD326.18K).

Compensation vs Earnings: Herve's compensation has increased whilst the company is unprofitable.

CEO

Herve Affagard (49 yo)

9.9yrs

Tenure

€1,368,888

Compensation

Mr. Herve Affagard is Co-Founder at MaaT Pharma SA and is its CEO since December 3, 2014. He is Director at MaaT Pharma SA since 2014.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Herve Affagard	CEO, Co-Founder & Director	9.9yrs	€1.37m	1.68% € 1.7m
Joel Dore	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Pierre Rimbaud	Co-Founder	no data	no data	no data
Sian Crouzet	CFO & Financial Director	8.8yrs	no data	no data
Carole Schwintner	Technology Director & Chief Technology Officer	no data	no data	no data
Nathalie Corvaia	Chief Scientific Officer	2.1yrs	no data	no data
Guilhaume Debroas	Head of Investor Relations	1.4yrs	no data	no data
Emilie Plantamura	Head of Clinical Development	1.4yrs	no data	no data
Jonathan Chriqui	Chief Business Officer	less than a year	no data	no data
Gianfranco Pittari	Chief Medical Officer	less than a year	no data	no data

1.4yrs

Average Tenure

Experienced Management: MAAT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Herve Affagard	CEO, Co-Founder & Director	10.8yrs	€1.37m	1.68% € 1.7m
Joel Dore	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Claude Bertrand	Independent Non-Executive Director	4.3yrs	€35.00k	no data
Karim Dabbagh	Independent Chairman	1.4yrs	€29.25k	0.014% € 14.1k
Jean Volatier	Independent Non Executive Director	3.8yrs	€45.00k	no data
Robert Jenq	Member of Scientific Advisory Board	4.5yrs	no data	no data
Ernst Holler	Chair of Scientific Advisory Board	4.5yrs	no data	no data
Florent Malard	Member of Scientific Advisory Board	4.5yrs	no data	no data
Robert Zeiser	Member of Scientific Advisory Board	4.5yrs	no data	no data
Jean-Marie Lefevre	Non-Executive Director	8.8yrs	no data	no data
Dorothee Burkel	Independent Non Executive Director	3.8yrs	€37.00k	no data
Nadia Kamal	Independent Director	1.4yrs	€24.25k	no data

4.5yrs

Average Tenure

60yo

Average Age

Experienced Board: MAAT's board of directors are considered experienced (4.5 years average tenure).

MaaT Pharma Management

Management criteria checks 1/4

Key information

Recent management updates

MaaT Pharma SA Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer

Maat Pharma SA Appoint Jonathan Chriqui as Chief Business Officer

MaaT Pharma SA, Annual General Meeting, May 28, 2024

High number of new directors

MaaT Pharma Announces Management Changes

MaaT Pharma SA, Annual General Meeting, Jun 19, 2023

Recent updates

MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease

First half 2024 earnings released: €1.05 loss per share (vs €0.76 loss in 1H 2023)

New major risk - Revenue and earnings growth

MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma SA Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer

New minor risk - Market cap size

New minor risk - Shareholder dilution

New minor risk - Market cap size

MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming to Improve Patients’ Responses to Immunotherapies

Full year 2023 earnings released

Maat Pharma SA Appoint Jonathan Chriqui as Chief Business Officer

MaaT Pharma SA, Annual General Meeting, May 28, 2024

MaaT Pharma SA to Report Fiscal Year 2023 Results on Mar 28, 2024

New major risk - Share price stability

MaaT Pharma SA Announces Its Ongoing Phase 2B Trial, Called Phoebus, Aimed At Evaluating MaaT033 to Improve Overall Survival for Patients Receiving allo-HSCT2

MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-Versus-Host Disease with MaaT013

New minor risk - Share price stability

First half 2023 earnings released

MaaT Pharma SA to Report Q3, 2023 Results on Nov 09, 2023

MaaT Pharma SA to Report First Half, 2023 Results on Sep 26, 2023

MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in AGvHD

High number of new directors

MaaT Pharma Announces Management Changes

MaaT Pharma SA, Annual General Meeting, Jun 19, 2023

Full year 2022 earnings released

MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma SA Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting

Price target increased to €19.30

Less than half of directors are independent

MaaT Pharma Appoints Nathalie Corvaia as Chief Scientific Officer

MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

Full year 2021 earnings released

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

Maat Pharma Announces Resignation Martine George as Member of Board of Directors, Effective June 1, 2022

Less than half of directors are independent

Full year 2021 earnings released

MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013

MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease

Maat Pharma Sa Announces Positive Interim Engraftment Data for Oral Formulation Maat033 Allowing Early Termination of Phase 1B Cimon Study

MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age